[go: up one dir, main page]

AU2000275972A1 - Pde iii inhibitors for treating sexual dysfunction - Google Patents

Pde iii inhibitors for treating sexual dysfunction

Info

Publication number
AU2000275972A1
AU2000275972A1 AU2000275972A AU7597200A AU2000275972A1 AU 2000275972 A1 AU2000275972 A1 AU 2000275972A1 AU 2000275972 A AU2000275972 A AU 2000275972A AU 7597200 A AU7597200 A AU 7597200A AU 2000275972 A1 AU2000275972 A1 AU 2000275972A1
Authority
AU
Australia
Prior art keywords
sexual dysfunction
treating sexual
pde iii
iii inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000275972A
Other languages
English (en)
Inventor
Neal R. Cutler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2000275972A1 publication Critical patent/AU2000275972A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2000275972A 2000-09-01 2000-09-21 Pde iii inhibitors for treating sexual dysfunction Abandoned AU2000275972A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/653,959 US6541487B1 (en) 1998-05-01 2000-09-01 PDE III inhibitors for treating sexual dysfunction
US09653959 2000-09-01
PCT/US2000/025835 WO2002019997A1 (fr) 2000-09-01 2000-09-21 Inhibiteurs pde iii pour le traitement de dysfonctions sexuelles

Publications (1)

Publication Number Publication Date
AU2000275972A1 true AU2000275972A1 (en) 2002-03-22

Family

ID=24622965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000275972A Abandoned AU2000275972A1 (en) 2000-09-01 2000-09-21 Pde iii inhibitors for treating sexual dysfunction

Country Status (3)

Country Link
US (1) US6541487B1 (fr)
AU (1) AU2000275972A1 (fr)
WO (1) WO2002019997A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101631A1 (en) 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
EP1699436A2 (fr) * 2003-12-12 2006-09-13 Myogen, Inc. Preparations a base d'enoximone et leur utilisation pour traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
JP2007530563A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
WO2005092333A1 (fr) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxyde et son utilisation dans le traitement de maladies induites par pde-iii
WO2006007213A1 (fr) * 2004-06-23 2006-01-19 Myogen, Inc. Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829991A (en) * 1987-01-06 1989-05-16 Medical Engineering Corp. Method and device for stimulating an erection
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
DE4338948A1 (de) * 1993-11-15 1995-05-18 Carlen Judith Verwendung von PDE-Inhibitoren bei der Behandlung erektiler Dysfunktionen
US6143762A (en) * 1996-08-14 2000-11-07 Smithkline Beecham, Plc Tetrahydroisoquinoline derivatives and their pharmaceutical use
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU740758B2 (en) * 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
AU734734B2 (en) * 1997-10-28 2001-06-21 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20020055702A1 (en) * 1998-02-10 2002-05-09 Anthony Atala Ultrasound-mediated drug delivery
US6132753A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6110489A (en) * 1998-05-01 2000-08-29 Cutler; Neal R. Use of quinolines and quinolones to treat male erectile dysfunction
US6194433B1 (en) * 1998-10-05 2001-02-27 Neal R. Cutler Sexual dysfunction in females
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
WO1999056666A1 (fr) 1998-05-01 1999-11-11 Rt Alamo Ventures, Inc. Traitement des troubles de la sexualite chez certains groupes de patients
AU5509099A (en) * 1998-08-03 2000-02-28 Basf Corporation Pyridinones for the treatment of sexual dysfunction
US6303135B1 (en) * 1999-07-08 2001-10-16 Neal R. Cutler Use of quinolines and quinolones to treat male erectile dysfunction

Also Published As

Publication number Publication date
US6541487B1 (en) 2003-04-01
WO2002019997A1 (fr) 2002-03-14

Similar Documents

Publication Publication Date Title
IL138907A0 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
AU2001259056A1 (en) Method for selectively inhibiting ghrelin action
PL363150A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2001244192A1 (en) Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction
AU2002238106A1 (en) Melanocortin metallopeptides for treatment of sexual dysfunction
AU8323701A (en) Inhibitors of p38
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU3894600A (en) Method of treating sexual dysfunction
PL360186A1 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
AU3776799A (en) Methods for treating female sexual dysfunction
HUP0300860A3 (en) Pharmaceutical compositions suitable for treatment of urinary dysfunction
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
AU2002246924A1 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
AU2001237379A1 (en) Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
AU2001264650A1 (en) Adrenal dysfunction
AU2002212162A1 (en) Incompetitive inhibitors of helicase primase
AU2002228911A1 (en) Methods for inhibiting pain
AU2001236440A1 (en) Method for the treatment of inflammation with spla2 inhibitors
AU2001229252A1 (en) Method for the treatment of renal dysfunction with spla2 inhibitors
AU2002336130A1 (en) Pyridin-2-YL-Methlyamine derivatives for treating opioid dependence